This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
You need good production, good science and engineering, and you need good lawyers. Drugs with an AB rating meet the required bioequivalence. More recently, Teva tried to reclassify the drug as a biologic as a move against generics producers, but a Washington, DC federal court issued a decision against that attempt.
It requires having access to proper techniques and skill sets, state-of-the-art equipment, process scientists and engineers who have a deep understanding of Quality by Design (QbD) principles, and methods for product and process characterisation. In vitro release testing to demonstrate bioequivalence.
These agencies set guidelines and regulations that generic drug manufacturers must follow to ensure that their products are bioequivalent to the innovator drug. One of the main challenges is ensuring bioequivalence with the innovator drug. ” National Academies of Sciences, Engineering, and Medicine , 2020.
platform and its large-capacity VV Cop TK”RR” oncolytic virus, engineered to encode both a Treg-depleting human recombinant anti-CTLA4 antibody generated by BioInvent’s n-CoDeR/F.I.R.S.T. Transgene and BioInvent International received regulatory approval in Belgium for a Phase I/IIa trial of oncolytic Vaccinia virus BT-001.
AstraZeneca has drawn criticism for saying it can’t share its vaccine tech with the WHO because it has no engineers available ‘to brief people and train them’ ( BI ).
Korea To Toughen Co-Bioequivalence Study System Amid Generic Quality Issue ( Pink Sheet ).
Coronavirus Pandemic.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content